Literature DB >> 9763561

The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity.

S Kangsadalampai1, P G Board.   

Abstract

There is a wide normal range of coagulation factor XIII activity that has never been adequately explained. A polymorphism substituting leucine for valine at position 34 in the activation peptide of the A subunit of factor XIII has recently been discovered in nondeficient individuals, and the present studies indicate that the leucine substitution results in a significant increase in transglutaminase activity. The frequency of the Leu34 allele in the Australian Caucasian population is 0.27, which is high enough to suggest that the inheritance of either the Val34 or Leu34 alleles may contribute to the wide normal range of activity. Although there has been structural evidence indicating that the activation peptide does not dissociate from the enzyme after thrombin cleavage, the discovery of elevated activity resulting from the Leu34 substitution is the first direct evidence that the activation peptide plays a continuing role in the function of factor XIII. Copyright 1998 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9763561

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  The impact of factor XIIIa V34L polymorphism on plasma factor XIII activity in the Chinese and Asian Indians from Singapore.

Authors:  Chew-Kiat Heng; Suman Lal; Nilmani Saha; Poh-Sim Low; M Ilyas Kamboh
Journal:  Hum Genet       Date:  2003-10-31       Impact factor: 4.132

2.  Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients.

Authors:  Ana Bronić; Goran Ferencak; Renata Zadro; Ana Stavljenić-Rukavina; Robert Bernat
Journal:  Mol Biol Rep       Date:  2007-09-27       Impact factor: 2.316

3.  Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population.

Authors:  Yu-Lin Ko; Lung-An Hsu; Tsu-Shiu Hsu; Chia-Ti Tsai; Ming-Sheng Teng; Semon Wu; Chi-Jen Chang; Ying-Shiung Lee
Journal:  Hum Genet       Date:  2005-12-14       Impact factor: 4.132

4.  Transglutaminases Derived from Astrocytes Accelerate Amyloid β Aggregation.

Authors:  Kenji Kawabe; Katsura Takano; Mitsuaki Moriyama; Yoichi Nakamura
Journal:  Neurochem Res       Date:  2017-04-09       Impact factor: 3.996

5.  Development and evaluation of a transfusion medicine genome wide genotyping array.

Authors:  Yuelong Guo; Michael P Busch; Mark Seielstad; Stacy Endres-Dighe; Connie M Westhoff; Brendan Keating; Carolyn Hoppe; Aarash Bordbar; Brian Custer; Adam S Butterworth; Tamir Kanias; Alan E Mast; Steve Kleinman; Yontao Lu; Grier P Page
Journal:  Transfusion       Date:  2018-11-20       Impact factor: 3.157

6.  The inflammatory response is influenced by FXIII VAL 34 LEU polymorphism in a human LPS model.

Authors:  Florian M Kovar; Claudia L Marsik; Bernd Jilma; Christine Mannhalter; Christian Joukhadar; Oswald F Wagner; Georg Endler
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

7.  Impact of hemostatic gene single point mutations in patients with non-diabetic coronary artery disease.

Authors:  Ahmet Var; Ozan Utük; Sinem Akçali; Tamer Sanlidağ; Bekir S Uyanik; Gönül Dinç
Journal:  Mol Biol Rep       Date:  2009-01-03       Impact factor: 2.316

8.  Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleeding.

Authors:  Ynte M Ruigrok; Arjen J C Slooter; Gabriel J E Rinkel; Cisca Wijmenga; Frits R Rosendaal
Journal:  Acta Neurochir (Wien)       Date:  2009-10-14       Impact factor: 2.216

Review 9.  Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?

Authors:  Wolfgang Korte
Journal:  J Blood Med       Date:  2014-07-09

10.  F13A1 Gene Variant (V34L) and Residual Circulating FXIIIA Levels Predict Short- and Long-Term Mortality in Acute Myocardial Infarction after Coronary Angioplasty.

Authors:  Lucia Ansani; Jlenia Marchesini; Gabriele Pestelli; Giovanni Andrea Luisi; Giulia Scillitani; Giovanna Longo; Daniela Milani; Maria Luisa Serino; Veronica Tisato; Donato Gemmati
Journal:  Int J Mol Sci       Date:  2018-09-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.